- Home
- LDWY vs AWH Comparison
LDWY vs AWH Comparison
Compare LDWY & AWH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDWY
- AWH
- Stock Information
- Founded
- LDWY 1990
- AWH 1993
- Country
- LDWY United States
- AWH United States
- Employees
- LDWY N/A
- AWH N/A
- Industry
- LDWY Advertising
- AWH Medical/Dental Instruments
- Sector
- LDWY Consumer Discretionary
- AWH Health Care
- Exchange
- LDWY Nasdaq
- AWH Nasdaq
- Market Cap
- LDWY 6.9M
- AWH 6.2M
- IPO Year
- LDWY 1991
- AWH N/A
- Fundamental
- Price
- LDWY $4.12
- AWH $0.22
- Analyst Decision
- LDWY
- AWH Buy
- Analyst Count
- LDWY 0
- AWH 2
- Target Price
- LDWY N/A
- AWH $4.40
- AVG Volume (30 Days)
- LDWY 5.3K
- AWH 298.1K
- Earning Date
- LDWY 03-31-2025
- AWH 03-27-2025
- Dividend Yield
- LDWY N/A
- AWH N/A
- EPS Growth
- LDWY N/A
- AWH N/A
- EPS
- LDWY N/A
- AWH N/A
- Revenue
- LDWY $31,581,000.00
- AWH $8,963,000.00
- Revenue This Year
- LDWY N/A
- AWH $11.87
- Revenue Next Year
- LDWY N/A
- AWH $79.10
- P/E Ratio
- LDWY N/A
- AWH N/A
- Revenue Growth
- LDWY N/A
- AWH N/A
- 52 Week Low
- LDWY $3.02
- AWH $0.21
- 52 Week High
- LDWY $6.88
- AWH $4.47
- Technical
- Relative Strength Index (RSI)
- LDWY 45.61
- AWH 21.26
- Support Level
- LDWY $3.85
- AWH $0.21
- Resistance Level
- LDWY $4.75
- AWH $0.36
- Average True Range (ATR)
- LDWY 0.17
- AWH 0.06
- MACD
- LDWY -0.01
- AWH -0.00
- Stochastic Oscillator
- LDWY 30.00
- AWH 4.76
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two Industry Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.
About AWH Aspira Women's Health Inc.
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.